Pfizer is interested in establishing alliances to develop and/or access:

• Patient cohorts with high quality longitudinal molecular and phenotypic data and/or DNA and appropriately-consented, IRB-approved tissue samples in diseases of interest to Pfizer for
  • clinical trials
  • data mining
  • biomarker studies
  • genetic and pharmaco-genomic studies
• Systems Biology/Pharmacology
  • Databases with high quality treatment and disease outcomes associated with genetic, as well as molecular (metabolomic, proteomic, transcriptomic, epigenetic, clinical chemistry markers) or functional measures in particular imaging data
  • Databases of searchable eQTLs, pQTLs across tissues
  • Disease biology guided combination therapy design platforms
  • Systems biology approaches and proven in silico tools to evaluate pharmacological perturbation and elucidate mechanisms of in vivo toxicity
  • Mining of data for correlation and understanding of causality
• Breakthrough diagnostic technologies that also are highly quantitative, require minimal specimen/ tissue, offer quick turnaround time and can be multiplexed.  This will include but not limited to:
  • Near-patient Point-of-Care technologies
  • Next Generation Sequencing technologies
  • Circulating cells
  • Circulating and urinary cell-free nucleic acids
  • Antigen receptor sequencing
  • Microbiome, including virome characterization
• In vivo imaging technologies (including MRI, PET, CT, optical imaging technologies, imaging agents, genetically encoded tags, etc.,) with particular interest in:
  • Imaging agents for small and large molecule compound distribution studies
  • Imaging agents monitoring physiology mechanisms and disease
  • Analytical tools and technologies
• Biospecimen Analysis
  • Circulating tumor cell and Nucleic Acid quantification and analysis
  • Multiplexed flow cytometry for leukocyte analysis
  • Automated IHC for tissue analysis (cancer, safety)
  • Advanced ADME — related genotyping
  • 3D cell models for safety and efficacy assessment that ideally incorporate genetic diversity
• Physiological Biomarkers
  • Technologies adding precision to pain management and treatment in pre-clinical and clinical studies
  • EEG-based biomarker for assessment of central pharmacology
• iPS cell resources and technologies to generate iPS cells that may be used to enable Precision Medicine strategies
  • Validated cell differentiation protocols
  • iPS cells derived from sub populations with specific genotypic/phenotypic data
  • Technology to create iPS cells in a rapid and reproducible fashion without insertional approaches